|
||
J. Exp. Med.,
Volume 188, Number 12, December 21, 1998 2349-2356
By



From the * Center for Biologics Evaluation and Research, Rockville, Maryland 20852; and the An endothelial cell inhibitor was purified from supernatant of an Epstein-Barr virus-immortalized cell line and identified as fragments of calreticulin. The purified recombinant NH2-terminal domain of calreticulin (amino acids 1-180) inhibited the proliferation of endothelial cells,
but not cells of other lineages, and suppressed angiogenesis in vivo. We have named this NH2-terminal domain of calreticulin vasostatin. When inoculated into athymic mice, vasostatin significantly reduced growth of human Burkitt lymphoma and human colon carcinoma. Compared with other inhibitors of angiogenesis, vasostatin is a small, soluble, and stable molecule
that is easy to produce and deliver. As an angiogenesis inhibitor that specifically targets proliferating endothelial cells, vasostatin has a unique potential for cancer treatment.
Laboratory of Cell Biology, the § Laboratory of Pathology, and the
Laboratory of Experimental
Carcinogenesis, National Cancer Institute, Bethesda, Maryland 20892
This article has been cited by other articles:
| TABLE OF CONTENTS |
|